AU2009298720C1 - Long term drug delivery devices with polyurethane-based polymers and their manufacture - Google Patents

Long term drug delivery devices with polyurethane-based polymers and their manufacture Download PDF

Info

Publication number
AU2009298720C1
AU2009298720C1 AU2009298720A AU2009298720A AU2009298720C1 AU 2009298720 C1 AU2009298720 C1 AU 2009298720C1 AU 2009298720 A AU2009298720 A AU 2009298720A AU 2009298720 A AU2009298720 A AU 2009298720A AU 2009298720 C1 AU2009298720 C1 AU 2009298720C1
Authority
AU
Australia
Prior art keywords
polyurethane
drug delivery
active agent
delivery device
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009298720A
Other languages
English (en)
Other versions
AU2009298720A1 (en
AU2009298720B2 (en
Inventor
Petr Kuzma
Harry Quandt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Braeburn Pharmaceuticals Inc
Original Assignee
Braeburn Pharmaceuticals BVBA SPRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Braeburn Pharmaceuticals BVBA SPRL filed Critical Braeburn Pharmaceuticals BVBA SPRL
Publication of AU2009298720A1 publication Critical patent/AU2009298720A1/en
Application granted granted Critical
Publication of AU2009298720B2 publication Critical patent/AU2009298720B2/en
Assigned to BRAEBURN PHARMACEUTICALS BVBA SPRL reassignment BRAEBURN PHARMACEUTICALS BVBA SPRL Request for Assignment Assignors: ENDO PHARMACEUTICALS SOLUTIONS INC.
Publication of AU2009298720C1 publication Critical patent/AU2009298720C1/en
Assigned to BRAEBURN PHARMACEUTICALS, INC. reassignment BRAEBURN PHARMACEUTICALS, INC. Request for Assignment Assignors: BRAEBURN PHARMACEUTICALS BVBA SPRL
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T29/00—Metal working
    • Y10T29/49—Method of mechanical manufacture
    • Y10T29/49826—Assembling or joining

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Polyurethanes Or Polyureas (AREA)
AU2009298720A 2008-09-30 2009-09-28 Long term drug delivery devices with polyurethane-based polymers and their manufacture Ceased AU2009298720C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/242,497 US7858110B2 (en) 2003-08-11 2008-09-30 Long term drug delivery devices with polyurethane based polymers and their manufacture
US12/242,497 2008-09-30
PCT/US2009/058571 WO2010039641A2 (en) 2008-09-30 2009-09-28 Long term drug delivery devices with polyurethane-based polymers and their manufacture

Publications (3)

Publication Number Publication Date
AU2009298720A1 AU2009298720A1 (en) 2010-04-08
AU2009298720B2 AU2009298720B2 (en) 2015-07-16
AU2009298720C1 true AU2009298720C1 (en) 2015-12-17

Family

ID=41594397

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009298720A Ceased AU2009298720C1 (en) 2008-09-30 2009-09-28 Long term drug delivery devices with polyurethane-based polymers and their manufacture

Country Status (13)

Country Link
US (5) US7858110B2 (https=)
EP (1) EP2344123A2 (https=)
JP (2) JP5677962B2 (https=)
KR (1) KR20110063536A (https=)
CN (1) CN102202647B (https=)
AU (1) AU2009298720C1 (https=)
BR (1) BRPI0920824A2 (https=)
CA (1) CA2739178C (https=)
IL (1) IL211954A0 (https=)
MX (1) MX2011003299A (https=)
RU (1) RU2508089C2 (https=)
UA (1) UA106593C2 (https=)
WO (1) WO2010039641A2 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090208540A1 (en) * 2003-08-11 2009-08-20 Indevus Pharmaceuticals, Inc. Implantable device for the delivery of naltrexone and methods of use thereof
US7858110B2 (en) * 2003-08-11 2010-12-28 Endo Pharmaceuticals Solutions, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
CA2437639C (en) * 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US20110236456A1 (en) * 2008-09-30 2011-09-29 Endo Pharmaceuticals Solutions Inc. Implantable device for the delivery of histrelin and methods of use thereof
CA2739181C (en) * 2008-09-30 2017-03-14 Endo Pharmaceuticals Solutions Inc. Implantable device for the delivery of risperidone and methods of use thereof
US9322103B2 (en) * 2010-08-06 2016-04-26 Microchips Biotech, Inc. Biosensor membrane composition, biosensor, and methods for making same
WO2012158779A1 (en) 2011-05-17 2012-11-22 Reprotect, Inc. Reusable intravaginal delivery device, system, and method
WO2012177825A1 (en) 2011-06-21 2012-12-27 Bvw Holding Ag Medical device comprising boswellic acid
WO2013013172A1 (en) * 2011-07-20 2013-01-24 The University Of Utah Research Foundation Intravaginal devices for drug delivery
HUE032240T2 (en) 2011-10-24 2017-09-28 Asana Biosciences Llc cyclohexylamines
CA2853251A1 (en) * 2011-10-24 2013-05-02 Endo Pharmaceuticals Solutions Inc. Implantable rasagiline compositions and methods of treatment thereof
EP3219310A3 (en) * 2011-10-24 2017-11-29 Braeburn Pharmaceuticals, Inc. Implantable drug delivery compositions and methods of treatment thereof
JP6149183B2 (ja) 2011-10-24 2017-06-21 ブレイバーン ファーマシューティカルズ，インコーポレイティド 移植可能チザニジン組成物及びその治療方法
WO2014052837A1 (en) * 2012-09-28 2014-04-03 Delpor, Inc. Device and methods for sustained release of antipsychotic medications
JP2016503424A (ja) * 2012-11-19 2016-02-04 ブレブルン ファーマシューティカルズ ベスローテン フェンノートシャップ メット ベペルクテ アーンスプラケリイクヘイト ソシエテ プリベー ア レスポンサビリテ リミテー 移植可能な薬剤送達組成物およびその治療方法
US20160022571A1 (en) * 2013-03-14 2016-01-28 Braeburn Pharmaceuticals Bvba Sprl Implantable drug delivery compositions comprising non-polymeric sorption enhancers and methods of treatment thereof
KR102557326B1 (ko) 2013-03-15 2023-07-19 타리스 바이오메디컬 엘엘씨 약물-투과성 구성요소를 가지는 약물 전달 장치
WO2015044415A1 (en) * 2013-09-30 2015-04-02 Universiteit Gent Polyurethanes as oral drug delivery platform
JP6616772B2 (ja) 2013-12-16 2019-12-04 アサナ・バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー Ｐ２ｘ３および／またはｐ２ｘ２／３化合物ならびに方法
US10076156B2 (en) 2014-08-27 2018-09-18 Nike, Inc. Article of footwear with soil-shedding performance
GB2532837B (en) 2014-08-27 2017-10-25 Nike Innovate Cv Article of footwear with soil-shedding performance
US10314364B2 (en) 2014-08-27 2019-06-11 Nike, Inc. Soil-shedding article of footwear, and method of using the same
WO2016033277A1 (en) 2014-08-27 2016-03-03 Nike Innovate C.V. Articles of footwear, apparel, and sports equipment with water absorbtion properties
US10070686B2 (en) 2014-08-27 2018-09-11 Nike, Inc. Soil-shedding article of footwear, components thereof, and methods of making the article
US10339559B2 (en) * 2014-12-04 2019-07-02 Adobe Inc. Associating social comments with individual assets used in a campaign
WO2016172704A1 (en) 2015-04-23 2016-10-27 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
US10531705B2 (en) 2016-03-02 2020-01-14 Nike, Inc. Hydrogel tie layer
US10455893B2 (en) 2016-03-02 2019-10-29 Nike, Inc. Hydrogel with mesh for soil deflection
US10675609B2 (en) 2016-03-02 2020-06-09 Nike, Inc. Articles with soil-shedding performance
US10362834B2 (en) 2016-03-02 2019-07-30 Nike, Inc. Hydrogel connection
CN109996546B (zh) 2016-09-30 2023-06-27 阿沙纳生物科学公司 P2x3和/或p2x2/3化合物及方法
TWI700175B (zh) 2017-08-01 2020-08-01 荷蘭商耐基創新公司 製造用於鞋類物品之外底的組件之方法
WO2019079715A1 (en) 2017-10-19 2019-04-25 Nike Innovate C.V. OUTSOLE AND MANUFACTURING METHOD THEREOF
CA3150272A1 (en) * 2019-08-13 2021-02-18 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of antiviral agents
CA3157003A1 (en) 2019-10-07 2021-04-15 Oak Crest Institute Of Science Orally implantable drug delivery device
CN114980861A (zh) 2019-11-27 2022-08-30 橡冠科学研究院 缓释药物递送装置
AU2022202053A1 (en) 2021-09-17 2023-04-06 Biocorrx, Inc. Biodegradable implant including naltrexone
US20250170254A1 (en) 2022-01-06 2025-05-29 Oak Crest Institute Of Science Subdermal Implant for Sustained Drug Delivery
EP4698151A1 (en) 2023-04-19 2026-02-25 Oak Crest Institute of Science Vaginal drug delivery device
WO2026055309A1 (en) 2024-09-04 2026-03-12 Oak Crest Institute Of Science Subdermal drug delivery devices

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5035891A (en) * 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
US5629008A (en) * 1992-06-02 1997-05-13 C.R. Bard, Inc. Method and device for long-term delivery of drugs
WO2005013936A2 (en) * 2003-08-11 2005-02-17 Valera Pharmaceuticals, Inc. Manufacture of long term drug delivery devices with polyurethane based polymers
US20060204540A1 (en) * 2005-03-11 2006-09-14 Petr Kuzma Controlled release formulations of octreotide

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3948254A (en) 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US3975350A (en) 1972-08-02 1976-08-17 Princeton Polymer Laboratories, Incorporated Hydrophilic or hydrogel carrier systems such as coatings, body implants and other articles
US4136145A (en) 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
US4207890A (en) 1977-01-04 1980-06-17 Mcneilab, Inc. Drug-dispensing device and method
US4131604A (en) 1977-11-23 1978-12-26 Thermo Electron Corporation Polyurethane elastomer for heart assist devices
US4207809A (en) 1978-03-20 1980-06-17 Restaurant Technology, Inc. Dual reservoir coffee urn
US4386039A (en) 1980-02-11 1983-05-31 Thermo Electron Corporation Process for forming an optically clear polyurethane lens or cornea
US4523005A (en) 1981-10-30 1985-06-11 Thermedics, Inc. Extrudable polyurethane for prosthetic devices prepared from a diisocyanate, a polytetramethylene ether polyol, and 1,4-butane diol
US4469671A (en) 1983-02-22 1984-09-04 Eli Lilly And Company Contraceptive device
US4751133A (en) 1984-11-13 1988-06-14 Thermedics, Inc. Medical patches and processes for producing same
US4673565A (en) * 1985-05-03 1987-06-16 E. I. Du Pont De Nemours And Company Pharmaceutical compositions containing hollow fine tubular drug delivery systems
JPS62223112A (ja) 1986-03-25 1987-10-01 Rooto Seiyaku Kk 歯周病治療剤
US4743673A (en) 1986-12-19 1988-05-10 Tyndale Plains-Hunter, Ltd. Hydrophilic carboxy polyurethanes
US5207705A (en) 1988-12-08 1993-05-04 Brigham And Women's Hospital Prosthesis of foam polyurethane and collagen and uses thereof
US5254662A (en) 1990-09-12 1993-10-19 Polymedia Industries, Inc. Biostable polyurethane products
AU651654B2 (en) 1992-01-14 1994-07-28 Endo Pharmaceuticals Solutions Inc. Manufacture of water-swellable hydrophilic articles and drug delivery devices
US5266325A (en) 1990-09-28 1993-11-30 Hydro Med Science Division Of National Patent Development Corp. Preparation of homogeneous hydrogel copolymers
CA2134087C (en) 1992-04-24 2007-07-17 Robert S. Ward Copolymers and non-porous, semi-permeable membrane thereof and its use for permeating molecules of predetermined molecular weight range
US5354835A (en) 1993-07-23 1994-10-11 Saudi Basic Industries Corporation Desalination process
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
WO1996024330A1 (en) 1995-02-10 1996-08-15 Medtronic, Inc. Method and device for administering analgesics
US5789411A (en) 1995-09-11 1998-08-04 Lance L. Gooberman P. C. Improvements to rapid opioid detoxification
ES2233768T3 (es) 1996-02-02 2005-06-16 Alza Corporation Liberacion prolongada de un agente activo utilizando un sistema implantable.
FR2752380B1 (fr) 1996-08-14 1998-10-30 Dow Corning Sa Procede de fabrication d'un dispositif a liberation controlee
AUPO251096A0 (en) 1996-09-23 1996-10-17 Cardiac Crc Nominees Pty Limited Polysiloxane-containing polyurethane elastomeric compositions
US7728049B2 (en) 1996-10-08 2010-06-01 Zamore Alan M Irradiation conversion of thermoplastic to thermoset polymers
US20010006677A1 (en) 1996-10-29 2001-07-05 Mcginity James W. Effervescence polymeric film drug delivery system
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
ES2182379T3 (es) 1997-12-22 2003-03-01 Alza Corp Membrana de regulacion del regimen de liberacion para dispositivos de administracion controlada de farmacos.
WO1999033449A1 (en) 1997-12-30 1999-07-08 Alza Corporation Beneficial agent delivery system with membrane plug
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
WO2001043726A1 (en) 1999-12-16 2001-06-21 Trident Technologies, Llc System and method for extended delivery of a therapeutic agent with its receptor loading dose
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
WO2001074555A1 (en) 2000-03-31 2001-10-11 Holy Norman L Compostable, degradable plastic compositions and articles thereof
CA2420854C (en) 2000-09-01 2013-07-30 Palmaya Pty Ltd Slow release pharmaceutical preparation and method of administering of same
US6887270B2 (en) 2002-02-08 2005-05-03 Boston Scientific Scimed, Inc. Implantable or insertable medical device resistant to microbial growth and biofilm formation
AU2003228083A1 (en) 2002-05-23 2003-12-12 Discure, Ltd. Joint and dental implants
US7858110B2 (en) 2003-08-11 2010-12-28 Endo Pharmaceuticals Solutions, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
US20090208540A1 (en) 2003-08-11 2009-08-20 Indevus Pharmaceuticals, Inc. Implantable device for the delivery of naltrexone and methods of use thereof
US20060110428A1 (en) * 2004-07-02 2006-05-25 Eugene Dejuan Methods and devices for the treatment of ocular conditions
GB0417078D0 (en) * 2004-07-30 2004-09-01 Angiomed Ag Flexible implant
PT1781264E (pt) 2004-08-04 2013-10-16 Evonik Corp Métodos para o fabrico de dispositivis de administração e dispositivos para a mesma
US20060257355A1 (en) * 2005-05-10 2006-11-16 Abiomed, Inc. Impregnated polymer compositions and devices using them
US20080004260A1 (en) 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
MX2009005444A (es) * 2006-11-22 2009-06-02 Organon Nv Sistema de suministro para un farmaco hidrofilico no esteroide no ionizado.
US8956602B2 (en) 2006-12-05 2015-02-17 Landec, Inc. Delivery of drugs
UA104866C2 (uk) 2008-06-25 2014-03-25 Ендо Фармас'Ютікалз Солюшнз Інк. Імплантат октреотиду, який містить вивільняючу речовину
CA2739181C (en) 2008-09-30 2017-03-14 Endo Pharmaceuticals Solutions Inc. Implantable device for the delivery of risperidone and methods of use thereof
CA2739180C (en) 2008-09-30 2017-12-19 Endo Pharmaceuticals Solutions Inc. Implantable device for the delivery of octreotide and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5035891A (en) * 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
US5629008A (en) * 1992-06-02 1997-05-13 C.R. Bard, Inc. Method and device for long-term delivery of drugs
WO2005013936A2 (en) * 2003-08-11 2005-02-17 Valera Pharmaceuticals, Inc. Manufacture of long term drug delivery devices with polyurethane based polymers
US20060204540A1 (en) * 2005-03-11 2006-09-14 Petr Kuzma Controlled release formulations of octreotide

Also Published As

Publication number Publication date
RU2508089C2 (ru) 2014-02-27
US20120231061A1 (en) 2012-09-13
CA2739178A1 (en) 2010-04-08
JP5677962B2 (ja) 2015-02-25
US8303977B2 (en) 2012-11-06
US8784865B2 (en) 2014-07-22
JP2012504138A (ja) 2012-02-16
US20090098182A1 (en) 2009-04-16
WO2010039641A3 (en) 2010-07-29
US8460274B2 (en) 2013-06-11
CN102202647B (zh) 2015-11-25
JP2014224137A (ja) 2014-12-04
RU2011117328A (ru) 2012-11-10
US20110184376A1 (en) 2011-07-28
EP2344123A2 (en) 2011-07-20
UA106593C2 (uk) 2014-09-25
IL211954A0 (en) 2011-06-30
AU2009298720A1 (en) 2010-04-08
JP5897077B2 (ja) 2016-03-30
CA2739178C (en) 2016-09-06
HK1157646A1 (zh) 2012-07-06
US20150105746A1 (en) 2015-04-16
US7858110B2 (en) 2010-12-28
CN102202647A (zh) 2011-09-28
AU2009298720B2 (en) 2015-07-16
BRPI0920824A2 (pt) 2018-05-29
MX2011003299A (es) 2011-06-09
US20140012222A1 (en) 2014-01-09
KR20110063536A (ko) 2011-06-10
WO2010039641A2 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
AU2009298720C1 (en) Long term drug delivery devices with polyurethane-based polymers and their manufacture
CA2739181C (en) Implantable device for the delivery of risperidone and methods of use thereof
JP2014224137A5 (https=)
US20210161994A1 (en) Implantable device for the delivery of octreotide and methods of use thereof
US20090208540A1 (en) Implantable device for the delivery of naltrexone and methods of use thereof
US20130302397A1 (en) Implantable device for the delivery of histrelin and methods of use thereof
HK1157646B (en) Long term drug delivery devices with polyurethane-based polymers and their manufacture
HK1160001B (en) Implantable device for the delivery of risperidone and methods of use thereof
HK1160001A (en) Implantable device for the delivery of risperidone and methods of use thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: BRAEBURN PHARMACEUTICALS BVBA SPRL

Free format text: FORMER APPLICANT(S): ENDO PHARMACEUTICALS SOLUTIONS INC.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 SEP 2015 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 SEP 2015

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: BRAEBURN PHARMACEUTICALS, INC.

Free format text: FORMER OWNER WAS: BRAEBURN PHARMACEUTICALS BVBA SPRL

MK14 Patent ceased section 143(a) (annual fees not paid) or expired